Douglas A Levine
#151,111
Most Influential Person Now
Researcher
Douglas A Levine's AcademicInfluence.com Rankings
Douglas A Levineengineering Degrees
Engineering
#6107
World Rank
#7412
Historical Rank
Electrical Engineering
#1773
World Rank
#1872
Historical Rank
Douglas A Levinecomputer-science Degrees
Computer Science
#7957
World Rank
#8373
Historical Rank
Data Science
#171
World Rank
#174
Historical Rank
Computational Linguistics
#1692
World Rank
#1710
Historical Rank
Machine Learning
#3124
World Rank
#3163
Historical Rank
Download Badge
Engineering Computer Science
Douglas A Levine's Degrees
- Masters Electrical Engineering Stanford University
Why Is Douglas A Levine Influential?
(Suggest an Edit or Addition)Douglas A Levine's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
- Inferring tumour purity and stromal and immune cell admixture from expression data (2013) (4215)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018) (1745)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Absolute quantification of somatic DNA alterations in human cancer (2012) (1607)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- OncoKB: A Precision Oncology Knowledge Base. (2017) (1317)
- Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
- Evaluating cell lines as tumour models by comparison of genomic profiles (2013) (1114)
- Resistance to therapy caused by intragenic deletion in BRCA2 (2008) (933)
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015) (838)
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
- Integrated genomic and molecular characterization of cervical cancer (2017) (762)
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer (2016) (672)
- Network modeling links breast cancer susceptibility and centrosome dysfunction. (2007) (628)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. (2012) (544)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. (2009) (529)
- Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012) (509)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. (2010) (441)
- Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers (2005) (428)
- A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. (2018) (381)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC) (2006) (373)
- A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. (2008) (371)
- Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities (2019) (366)
- What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? (2007) (357)
- A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 (2010) (341)
- The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. (2006) (315)
- Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. (2004) (294)
- Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* (2014) (292)
- Recurrent SMARCA4 mutations in small cell carcinoma of the ovary (2014) (276)
- Integrated Molecular Characterization of Uterine Carcinosarcoma. (2017) (271)
- Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers (2013) (269)
- Genomic and biological characterization of exon 4 KRAS mutations in human cancer. (2010) (262)
- Common variants at 19p13 are associated with susceptibility to ovarian cancer (2010) (262)
- An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). (2012) (254)
- Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. (2014) (239)
- BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. (2009) (208)
- Gene expression signature with independent prognostic significance in epithelial ovarian cancer. (2004) (208)
- Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. (2003) (199)
- Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? (2009) (199)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. (2012) (196)
- Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma (2012) (187)
- The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology (2007) (178)
- A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. (2014) (176)
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer (2013) (172)
- Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations (2015) (171)
- Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. (2016) (168)
- Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer (2013) (167)
- Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. (2014) (163)
- Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups (2018) (163)
- The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. (2010) (162)
- Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy (2020) (156)
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. (2020) (155)
- Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers (2018) (154)
- The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. (2008) (154)
- The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. (2005) (153)
- Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. (2006) (152)
- Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
- Unique gene expression profile based on pathologic response in epithelial ovarian cancer. (2005) (143)
- Platelets reduce anoikis and promote metastasis by activating YAP1 signaling (2017) (141)
- Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. (2006) (140)
- Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. (2011) (139)
- Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen (2010) (133)
- Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma (2017) (133)
- Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? (2009) (132)
- Cancer-Related Infertility in Survivorship (2009) (127)
- Risk of endometrial carcinoma associated with BRCA mutation. (2001) (126)
- Intraepithelial T cells and tumor proliferation (2009) (122)
- Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study (2016) (122)
- Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma (2019) (119)
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. (2016) (119)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 (2013) (110)
- Genomic complexity and AKT dependence in serous ovarian cancer. (2012) (110)
- Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma (2012) (110)
- Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma (2010) (109)
- A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. (2010) (104)
- Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade (2017) (104)
- Time to Recurrence and Survival in Serous Ovarian Tumors Predicted from Integrated Genomic Profiles (2011) (104)
- Identification of Tumor Suppressors and Oncogenes from Genomic and Epigenetic Features in Ovarian Cancer (2011) (98)
- Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis (2007) (97)
- Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC) (2013) (96)
- Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. (2016) (96)
- A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus (2011) (92)
- Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. (2016) (92)
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. (2018) (91)
- Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance (2012) (90)
- A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. (2009) (89)
- Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations (2013) (83)
- Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant (2018) (83)
- Genome-wide significant risk associations for mucinous ovarian carcinoma (2015) (81)
- Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping (2015) (80)
- Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type (2016) (80)
- Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer (2012) (80)
- Uterine adenosarcomas are mesenchymal neoplasms (2016) (79)
- Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. (2015) (79)
- The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. (2016) (77)
- The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. (2001) (77)
- Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. (2016) (76)
- BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
- A microRNA survival signature (MiSS) for advanced ovarian cancer. (2011) (75)
- A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. (2010) (73)
- Pathologic Scoring of PTEN Immunohistochemistry in Endometrial Carcinoma is Highly Reproducible (2012) (70)
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
- A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome (2017) (70)
- Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. (2015) (68)
- Shared heritability and functional enrichment across six solid cancers (2018) (67)
- Two Estrogen-Related Variants in CYP19A1 and Endometrial Cancer Risk: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (2009) (66)
- New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair (2014) (66)
- Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery (2015) (66)
- CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (2019) (65)
- Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome (2009) (64)
- Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. (2007) (64)
- Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. (2015) (63)
- Laparoscopic management of adnexal masses in premenopausal and postmenopausal women. (1999) (62)
- Prognostic gene expression signature for high-grade serous ovarian cancer (2020) (61)
- IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. (2007) (60)
- Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. (2016) (60)
- The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in Non-Hispanic White Women (2011) (60)
- Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. (2007) (60)
- Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase (2011) (58)
- Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. (2020) (58)
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
- Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. (2012) (58)
- DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells (2014) (57)
- Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type (2015) (57)
- ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. (2013) (57)
- The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing (2011) (56)
- Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? (2016) (55)
- BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas (2013) (54)
- Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing (2017) (54)
- The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma (2005) (54)
- Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. (2007) (53)
- Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer (2015) (50)
- UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples (2015) (50)
- The role of pH in the development of tachyphylaxis to local anesthetic agents. (1968) (50)
- A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. (2018) (49)
- Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. (2010) (48)
- A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery. (2009) (47)
- A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission (2007) (46)
- Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger. (2011) (46)
- A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
- Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. (2015) (43)
- Prognostic Significance of Supradiaphragmatic Lymphadenopathy Identified on Preoperative Computed Tomography Scan in Patients Undergoing Primary Cytoreduction for Advanced Epithelial Ovarian Cancer (2010) (43)
- Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. (2013) (42)
- Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. (2014) (42)
- Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines (2020) (41)
- Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. (2012) (41)
- Small cell cancers of the female genital tract: Molecular and clinical aspects. (2018) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Is It Time to Centralize Ovarian Cancer Care in the United States? (2016) (40)
- Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study (2018) (40)
- Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer (2016) (39)
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis (2021) (39)
- A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. (2015) (38)
- Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. (2018) (37)
- Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1&bgr; (2015) (37)
- Molecular profiling of endometrial cancers from African-American and Caucasian women. (2006) (37)
- Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach. (2005) (37)
- Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion (2015) (36)
- Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency (2014) (36)
- Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity. (2015) (36)
- Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk (2015) (36)
- Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. (2016) (35)
- Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome12 (2015) (35)
- Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. (2002) (35)
- Racial disparities in molecular subtypes of endometrial cancer. (2018) (35)
- Endometrial cancer (2021) (33)
- The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. (2014) (33)
- Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. (2012) (32)
- Two Distinct Categories of Focal Deletions in Cancer Genomes (2013) (32)
- The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility (2016) (31)
- Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. (2015) (31)
- Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium (2015) (31)
- Risk of Endometrial Carcinoma Associated With BRCA Mutation (2001) (31)
- Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. (2016) (31)
- Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. (2012) (30)
- Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
- Gastrointestinal adenocarcinoma arising in a mature cystic teratoma of the ovary. (2004) (29)
- Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. (2018) (29)
- Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. (2009) (29)
- Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. (2021) (29)
- Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. (2017) (28)
- MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing (2019) (28)
- Comprehensive Quantitative Analysis of Ovarian and Breast Cancer Tumor Peptidomes (2014) (28)
- Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity. (2013) (28)
- Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. (2017) (28)
- Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach. (2012) (28)
- Comprehensive mutation profiling by next‐generation sequencing of effusion fluids from patients with high‐grade serous ovarian carcinoma (2015) (27)
- The 6q22.33 Locus and Breast Cancer Susceptibility (2009) (27)
- Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) (2015) (26)
- miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas (2017) (24)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (24)
- Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes (2016) (23)
- Pathologic Analysis of Ex Vivo Plasma Energy Tumor Destruction in Patients With Ovarian or Peritoneal Cancer (2010) (23)
- Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. (2017) (23)
- Assessing the genetic architecture of epithelial ovarian cancer histological subtypes (2016) (22)
- Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer (2019) (22)
- Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome (2013) (22)
- Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. (2008) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma (2012) (22)
- Update in the management of endometrial cancer. (2002) (21)
- Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. (2014) (21)
- Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk (2015) (21)
- Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted? (2013) (21)
- Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome (2014) (20)
- Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. (2009) (20)
- Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. (2008) (20)
- Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials (2017) (19)
- Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci (2017) (19)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. (2009) (17)
- Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. (2015) (17)
- A Prospective Randomized Trial Comparing Patient-Controlled Epidural Analgesia to Patient-Controlled Intravenous Analgesia on Postoperative Pain Control and Recovery After Major Open Gynecologic Cancer Surgery (2009) (17)
- Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer. (2018) (17)
- Blocking and Randomization to Improve Molecular Biomarker Discovery (2014) (17)
- A perception-based nanosensor platform to detect cancer biomarkers (2021) (17)
- Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers (2018) (16)
- Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene (2017) (16)
- Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. (2020) (16)
- Molecular Subtypes of Uterine Leiomyosarcoma and Correlation (2015) (15)
- Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk. (2020) (15)
- Genetic predisposition to bevacizumab-induced hypertension. (2017) (15)
- Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma (2020) (15)
- Prophylactic surgery in hereditary breast/ovarian cancer syndrome. (2003) (15)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17 q 21 . 31 (2013) (14)
- Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. (2004) (14)
- Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube and primary peritoneal cancer: A change in surgical approach (2004) (13)
- Transcript expression in endometrial cancers from Black and White patients. (2013) (13)
- Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives. (2020) (13)
- Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine. (2016) (13)
- The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair (2017) (13)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (12)
- Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. (2014) (11)
- Complex Atypical Hyperplasia of the Uterus: Characteristics and Prediction of Underlying Carcinoma Risk (2011) (11)
- Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. (2016) (11)
- Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer (2016) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration (2016) (10)
- Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. (2013) (10)
- WISP: A prospective, multi-center trial of salpingectomy with delayed oophorectomy versus risk reducing salpingo-oophorectomy in women at increased risk for hereditary ovarian cancer (2019) (10)
- FrequentMutation of the PIK 3 CA Gene in Ovarian and Breast Cancers (2005) (10)
- Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer (2014) (10)
- Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility (2018) (9)
- Exosomal microRNAs step into the biomarker arena. (2008) (8)
- Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence (2016) (8)
- State of the science: Uterine carcinosarcomas: From pathology to practice. (2021) (8)
- Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia (2015) (8)
- Analysis of N-glycoproteins using genomic N-glycosite prediction. (2013) (8)
- Atlas of Procedures in Gynecologic Oncology (2003) (8)
- Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers. (2010) (7)
- Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening (2021) (7)
- WNK1 haplotypes and bevacizumab-induced hypertension (2008) (7)
- Non-equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations (2013) (7)
- Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma (2018) (6)
- Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer. (2013) (6)
- BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor (2013) (6)
- Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers (2018) (6)
- Specific monoclonal antibodies. (1984) (6)
- A targeted genetic association study of epithelial ovarian cancer susceptibility (2016) (6)
- Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction (2004) (5)
- Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression. (2020) (5)
- Exploring the relationship between homologous recombination score and progression-free survival in BRCA wildtype ovarian carcinoma: Analysis of veliparib plus carboplatin/paclitaxel in the velia study (2020) (5)
- Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women (2019) (5)
- A pair of datasets for microRNA expression profiling to examine the use of careful study design for assigning arrays to samples (2018) (5)
- Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. (2021) (5)
- Joint IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research. (2021) (5)
- Cancer Biology and Signal Transduction New Insights into PARP Inhibitors ' Effect on Cell Cycle and Homology-Directed DNA Damage Repair (2014) (4)
- rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) (4)
- Computed Tomography Measures of Inter-site tumor Heterogeneity for Classifying Outcomes in High-Grade Serous Ovarian Carcinoma: a Retrospective Study (2019) (4)
- A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors. (2010) (4)
- Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
- The 6 q 22 . 33 Locus and Breast Cancer Susceptibility (2009) (4)
- Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P (2018) (4)
- Improved overall survival for patients with advanced ovarian, tubal, and primary peritoneal carcinoma as a result of a change in surgical approach: A follow-up study (2007) (4)
- Correction: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer (2016) (4)
- No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival (2016) (3)
- Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second‐look assessment (2008) (3)
- 0231: Response and Outcomes in Elderly Patients with Stage Iiic-Iv Ovarian Cancer Receiving Platinum- Taxane Chemotherapy (2006) (3)
- Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. (2019) (3)
- Abstract AP01: HE4 IS A BIOMARKER FOR NEWLY DIAGNOSED AND RECURRENT HIGH–GRADE SEROUS OVARIAN CANCERS WITH NORMAL CA–125 VALUES (2017) (3)
- Sentinel lymph node mapping for grade 1/2 endometrial cancer with superficial myoinvasion: Less is more (2011) (3)
- 5Risk of developing uterine corpus cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (2014) (3)
- Abstract 3303: A comprehensive TCGA Pan-Cancer molecular study of gynecologic and breast cancers (2018) (3)
- A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal, and peritoneal carcinoma (2007) (3)
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer (2016) (3)
- Intra-thoracic cytoreduction of stage IV peritoneal malignancy: a case series. (2008) (3)
- Abstract 133: Integrated molecular characterization of uterine carcinosarcoma in The Cancer Genome Atlas (TCGA) project (2016) (3)
- Late-Breaking Abstract 4: The Cancer Genome Atlas (TCGA) project on endometrial carcinoma: Initial data and preliminary genomic analysis (2012) (3)
- State of the science: Uterine sarcomas: From pathology to practice. (2020) (3)
- Uterine washing biomarkers as a novel screening tool for high-grade serous carcinoma (2013) (3)
- A catalogue of cancer-driving mutations in healthy tissue (2020) (3)
- Mechanisms of response to anti-angiogenesis therapy in CTNNB1-mutated endometrial cancers (2019) (2)
- Abstract PR02: Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition (2018) (2)
- Frequency of BRCA1 and BRCA2 germline mutations in uterine serous carcinomas and uterine carcinosarcomas. (2018) (2)
- MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing (2019) (2)
- Common variants at the CHEK 2 gene locus and risk of epithelial ovarian cancer (2015) (2)
- The evolving pathogenesis model of high-grade pelvic serous carcinoma. (2011) (2)
- Atlas of Procedures in Gynecologic Oncology, Third Edition (2008) (2)
- Sentinel lymph node mapping in patients with vulvar malignancies using indocyanine green and near-infrared imaging: Preliminary detection rate experience (2015) (2)
- Sentinel lymph node mapping in patients with endometrial cancer undergoing robot-assisted or standard laparoscopic procedures (2011) (2)
- A comprehensive analysis of BRAF and KRAS mutation status in low-grade serous (LGS) and serous borderline (SB) ovarian cancer (OC). (2012) (2)
- Abstract A05: BRCA1 promoter hypermethylation loss in recurrent high-grade serous carcinoma. (2016) (2)
- A feasible roadmap for unsupervised deconvolution of two-source mixed gene expressions (2013) (2)
- CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma (2020) (2)
- Abstract 1151: IL-8, VEGF and IGF-1 play the important role in ARHI mediated-tumor dormancy in ovarian cancer (2016) (2)
- PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study. (2016) (2)
- #GeneticTesting: Using Social Media to Facilitate Communication about testing to Women (Preprint) (2021) (1)
- A multicenter prospective assessment of surgical findings associated with suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer (2015) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Gene expression profiles of high-grade serous ovarian cancers in patients with normal CA-125 levels at the time of recurrence (2014) (1)
- An analysis of the survival outcomes of video-assisted thoracic surgery in the primary management of patients with advanced ovarian, tubal, and peritoneal cancer (2014) (1)
- Drug-induced adaptation along a resistance continuum in cancer cells (2022) (1)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (1)
- Erratum to: Lu Z, Baquero MT, Yang H, Yang M, Reger AS, Kim C, Levine DA, Clarke CH, Liao WS, Bast Jr RC. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 2014; 10:1071–92 (2014) (1)
- Nomogram for predicting 5-year survival after primary surgery for epithelial ovarian cancer. (2009) (1)
- Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction. (2004) (1)
- Mouse genome by 5-iododeoxyuridine with the activation of an endogenous murine leukemia virus. (1979) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- BRCA 1/2 Somatic Mutations in Patients with Advanced or Recurrent Endometrial Cancer (2020) (1)
- Abstract A46: Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis (2013) (1)
- Platelets reduce anoikis and promote metastasis by activating YAP1 signaling (2017) (1)
- 44th Annual Meeting of the American Society of Clinical Oncology. (2008) (1)
- Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. (2015) (1)
- Genomic mutation profiles of paired ovarian cancers (OC) across time. (2018) (1)
- Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening (2019) (1)
- Characterization of new Ashkenazi Jewish founder mutations in MSH6 causing Lynch syndrome. (2010) (1)
- Abstract 3970: PARP inhibitors increase expression of Type I interferon regulated genes mainly through trapping (2019) (1)
- Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
- Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study. (2015) (1)
- BRCA1 immunohistochemistry in high-grade serous ovarian cancers (HGS-OC) characterized for BRCA1 germ-line mutations. (2012) (1)
- Abstract 3422: The influence of genetic and clinical factors on the outcome following a diagnosis of small cell carcinoma of the ovary, hypercalcemic type (2016) (1)
- Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma (2022) (1)
- The limits of aggressive surgical cytoreduction. (2018) (1)
- Optimal Strategies for Therapy and Screening (2021) (1)
- Abstract CT269: A phase 2 study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007 (2020) (1)
- A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007. (2020) (1)
- Mechanisms of SWI/SNF dysfunction in the immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type (2019) (1)
- Racial differences in molecular subtypes between black and white patients with endometrial cancer (2017) (1)
- Is it time to centralize ovarian cancer care in the United States (2016) (1)
- DNA mismatch repair protein defects and endometrial cancer in women age 40 and younger. (2009) (1)
- KLF6-SV1 is a novel uterine leiomyosarcoma gene: From transgenic mouse model to human disease (2011) (0)
- Abstract PR18: Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8, and IGF-1 in the tumor microenvironment. (2016) (0)
- Maximizing minimally invasive surgical approaches in the morbidly obese patient with newly diagnosed uterine cancer (2014) (0)
- Abstract A24: A possible role for GSK3β in epithelial ovarian cancer chemoresistance by epigenetic regulation (2013) (0)
- Uterine leiomyosarcomas have reproducible molecular subtypes that correlate with survival (2013) (0)
- Characterization of actionable somatic alterations in microdissected gynecologic carcinosarcomas. (2016) (0)
- Patterns of recurrence and associated clinical factors in patients with advanced serous ovarian cancer who experience a CA125 negative recurrence (2012) (0)
- A catalogue of cancer-driving mutations in healthy tissue (2020) (0)
- Abstract B26: Immune-active microenvironment in SCCOHT: Rationale for therapy with immune checkpoint blockade (2018) (0)
- Atlas of Procedures in Gynecologic Oncology: Memorial Sloan‐Kettering Cancer Center (2003) (0)
- Uterine leiomyosarcomas are driven by cell cycle deregulation (2012) (0)
- The congressionally directed medical research programs’ Ovarian Cancer Academy: a new approach to training in biomedical research (2022) (0)
- Improvement in rates of cytoreduction to no residual for stages IIIB–IV ovarian, fallopian tube and primary peritoneal cancer: A change in surgical approach and individualized surgeon feedback (2015) (0)
- Abstract LB-342: MicroRNA-130b contributes to mesenchymal differentiation and leiomyosarcomagenesis (2011) (0)
- Integrated genomic analysis of STIC-associated high-grade serous carcinoma (2015) (0)
- Abstract 4168: PI3K/AKT pathway alterations in paired primary and recurrent endometrial carcinoma (2011) (0)
- RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer (2011) (0)
- Hereditary breast and ovarian cancer syndrome based on family history alone and implications for patients with serous carcinoma (2011) (0)
- Mutation profiles of paired ovarian cancers across time (2019) (0)
- Development and assessment of an accessible communication system for population-based genetic testing: Method/design (Preprint) (2021) (0)
- Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer (2016) (0)
- Immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type provides a rationale for evaluating immunotherapies to treat this malignancy (2018) (0)
- Abstract PR01: EMSY impairs DNA damage repair in a phosphorylation-dependent manner. (2016) (0)
- Abstract B15: Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. (2016) (0)
- Tumor-derived serum exosomal microRNA as a novel biomarker for high-grade serous carcinoma (2015) (0)
- Abstract B14: Molecular characterization of mucinous ovarian carcinoma. (2016) (0)
- Abstract 3158: Transcription factor SOX11 decreases viability in ovarian carcinoma cells. (2013) (0)
- University of Southern Denmark Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers (2018) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Frequency of the cancer genome atlas expression subtypes differs between early and advanced stage high grade serous ovarian cancers (2012) (0)
- Gynecologic cancer genomics in the modern era. (2013) (0)
- TCGA-based risk stratification of early-stage, high-grade endometrioid endometrial carcinoma (2016) (0)
- Abstract 4028: ARHI plays a critical role in ovarian cancer tumor dormancy by inhibition of angiogenesis switch (2015) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Using Social Media to Facilitate Communication About Women’s Testing: Tool Validation Study (2022) (0)
- An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study (2022) (0)
- Genetics in the development of endometrial cancer: How does it affect East Asians? (2017) (0)
- Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer (2016) (0)
- Risk prediction model for surgical site infections in patients undergoing gynecologic cancer surgery (2016) (0)
- Large-scale proteomic analysis of mechanisms of response to anti-angiogenesis therapy in -mutated endometrial cancers (2019) (0)
- The prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced stage epithelial ovarian cancer. (2009) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer (2015) (0)
- Allele-specific signal modeling and normalization improves "In silico detection of genomic deletion types and correction of normal cell contamination in copy number data" (2013) (0)
- Abstract 3422: miR-200c-driven mesenchymal-to-epithelial transition as a therapeutic target in uterine carcinosarcomas (2017) (0)
- Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for advanced ovarian cancer. (2010) (0)
- Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer (2019) (0)
- Mendelian randomization Association of vitamin D levels and risk of ovarian cancer : a Mendelian randomization study (2016) (0)
- 231 Patterns of Tumor Evolution in High-grade Ovarian Adenocarcinoma (2012) (0)
- Abstract 184: The role of matrix metalloproteinases (MMPs) andCTNNB1mutations in endometrial carcinoma (2019) (0)
- Development and assessment of an accessible communication system for population based genetic testing (Preprint) (2021) (0)
- SPL-108 mediates metastasis and chemoresistance in high-grade serous tubo-ovarian carcinoma (2021) (0)
- Effect of genetic testing results on patient-reported quality of life among patients undergoing panel testing for newly diagnosed ovarian cancer. (2020) (0)
- Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
- Predictive value of the age-adjusted Charlson comorbidity index on perioperative complications and survival in patients undergoing surgery for advanced ovarian cancer (2015) (0)
- The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma. (2022) (0)
- Abstract LB-A04: Transcriptional regulatory programs in gynecological cancers (2018) (0)
- Fallopian T ube a nd P rimary P eritoneal C arcinomas A ssociated With BRCA Mutations (2003) (0)
- Comprar Principles and Practice of Gynecologic Oncology Handbook | Dr. Douglas A. Levine M.D. | 9780781778480 | Lippincott Williams & Wilkins (2010) (0)
- Does intraoperative hypothermia contribute to postoperative morbidity in patients undergoing optimal primary surgical cytoreduction for advanced ovarian cancer (2012) (0)
- Abstract 4504: Genetic determinants of AKT-dependence in epithelial ovarian cancer (2010) (0)
- CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (2019) (0)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (0)
- miR-200C inhibits growth of uterine carcinosarcoma cells by driving a mesenchymal-to-epithelial transition (2016) (0)
- Abstract B26: Non-catalytic effects of PARP inhibitors in the context of cell cycle and homology-directed DNA damage repair (2013) (0)
- Abstract 4550: Differential PARP inhibitors' effects on cell cycle and consequently homologous DNA damage repair (2014) (0)
- Somatic mutations in small cell carcinoma of the ovary (2014) (0)
- Comprar Handbook for Principles and Practice of Gynecologic Oncology | Douglas A. Levine | 9780781778480 | Lippincott Williams & Wilkins (2010) (0)
- Focused Plenary I: Translational Research, Concept to Clinic (2014) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- 318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007 (2020) (0)
- Clinical outcome of Serous Tubal Intraepithelial Carcinomas (STIC) (2012) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract 2988 : DOK 2 suppression by methylation induces platinum resistance via suppression of apoptosis in ovarian cancer cells (2019) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Shared heritability and functional enrichment across six solid cancers (2019) (0)
- Interval Salpingectomy and Delayed Oophorectomy Versus Risk-Reducing Salpingo-Oophorectomy in Women at Risk for Hereditary Ovarian Carcinoma: A Prospective Multi-Site Trial (2020) (0)
- Abstract 4922: Patterns of tumor evolution in high grade serous ovarian carcinoma (2012) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract 30: Identification of genomic and epigenetic features of tumor suppressors and oncogenes in ovarian cancer (2011) (0)
- Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project (2015) (0)
- Abstract LB-91: SMARCA4 mutations in small cell carcinoma of the ovary (2014) (0)
- A comprehensive proteogenomic analysis of uterine cancer (2019) (0)
- Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study (2022) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- PARP and ABCB1 (MDR1) inhibitor treatment of ovarian cancer cell lines and PDX models demonstrate no synergistic effect (244) (2022) (0)
- Retraction to "A3' UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer" [Gynecol. Oncol. 120 (2011) S3]. (2011) (0)
- Abstract A26: Molecular analysis of short- vs. long-term ovarian cancer survivors (2020) (0)
- Optimizing gynecologic surgery for the morbidly obese patient with a surgical safety pathway (2019) (0)
- Abstract 3780: Spatially resolved transcriptional patterns of PARP inhibitor-resistant high grade serous ovarian cancer PDX tissue (2019) (0)
- Abstract A03: The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair (2017) (0)
- Abstract 2029: Identification of novel tumor suppressor microRNAs implicated in epithelial ovarian cancer from the 19q13.41 non-coding RNA cluster (2010) (0)
- Machine-Perception Nanosensor Platform to Detect Cancer Biomarkers (2021) (0)
- Robotic radical hysterectomy: Extent of tumor resection and operative outcomes compared with laparoscopy and exploratory laparotomy (2011) (0)
- Abstract 2975: Two putative founder MSH6 mutations associated with inherited cancer susceptibility in Ashkenazi Jewish population (2010) (0)
- Isaac Kinde Endometrial Cancers Evaluation of DNA from the Papanicolaou Test to Detect Ovarian (2013) (0)
- randomization Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study (2016) (0)
- BACOM2: a Java tool for detecting normal cell contamination of copy number in heterogeneous tumor (2015) (0)
- Risk-reducing surgery for BRCA mutations: Are we adhering to the guidelines? (2018) (0)
- Combined preoperative and extended pharmacologic venous thromboembolic prophylaxis in patient undergoing surgery for advanced adnexal malignancies (2015) (0)
- Anesthesia for patients with prosthetic heart valves. (1967) (0)
- PD-0332991, a cyclin-dependent kinase 4/6 inhibitor, is an active agent in uterine cancer cells (2014) (0)
- Abstract PR006: Correlation of immunohistochemistry with TP53 sequence and clinical outcomes in GOG-086P (2021) (0)
- Abstract 531: The cGAS-STING pathway as a driver of the immune-reactive microenvironment in small cell carcinoma of the ovary, hypercalcemic type (2019) (0)
- Abstract IA1: Mining the TCGA (2013) (0)
- Does minimally invasive surgery compromise the oncologic outcome of women with high-risk non-endometrioid endometrial carcinomas (2014) (0)
- Treatment with carboplatin and taxane chemotherapy increases T-cell receptor (TCR) clonality in high-grade serous ovarian cancer (HGSOC) (2017) (0)
- Genetic counselor involvement with abnormal immunohistochemistry results improves genetic testing in patients with endometrial cancer (2019) (0)
- Abstract 184: The role of matrix metalloproteinases (MMPs) and CTNNB1 mutations in endometrial carcinoma (2019) (0)
- Eighth International Symposium on hereditary breast and ovarian cancer (2021) (0)
- Toward Personalized Ovarian Cancer Therapy through the Cancer Genome Atlas (2011) (0)
- Abstract 3144: A role for DOK2 methylation in platinum resistance and tumor suppression in ovarian cancer (2012) (0)
- Introduction: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium (2019) (0)
- Assessing the genetic architecture of epithelial ovarian cancer histological subtypes (2016) (0)
- Central venous catheter placement (2013) (0)
- PI3K/AKT pathway alterations in paired primary and recurrent endometrial carcinoma (2012) (0)
- Abstract 1047: Suppression of the chromatin remodeling protein CHD3 and platinum resistance in ovarian cancer (2012) (0)
- 3144 : A role for DOK 2 methylation in platinum resistance and tumor suppression in ovarian cancer (2017) (0)
- Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma (2017) (0)
- Molecular characterization of mucinous ovarian cancer (2016) (0)
- Ki67 expression as a predictor for suboptimally debulked patients with advanced epithelial ovarian cancer (2007) (0)
- Why do patients decline cascade testing in families with an identified mutation associated with hereditary gynecologic cancers? (2020) (0)
- Comprar Atlas of Procedures in Gynecologic Oncology, Second Edition | Douglas A. Levine | 9781841844985 | Informa Healthcare (2008) (0)
- Identification and Characterization of Hematopoietic Stem (HSC)/Progenitor Cells in Human Solid Tumors (2008) (0)
- Abstract 2988: DOK2 suppression by methylation induces platinum resistance via suppression of apoptosis in ovarian cancer cells. (2013) (0)
- Blocking and randomization to improve molecular biomarker discovery. (2014) (0)
- Primary fallopian tube lesions in BRCA mutation carriers undergoing risk-reducing surgery. (2010) (0)
- Variation in NFk B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer (2014) (0)
- Molecular profiling of patients with curatively treated advanced serous ovarian carcinoma from The Cancer Genome Atlas (2011) (0)
- Abstract A31: The two most potent PARP inhibitors increase expression levels of innate immune response genes in BRCA wild-type HGSC tumors (2020) (0)
- Detection of sentinel lymph nodes using indocyanine green and near-in- frared fluorescence imaging for gynecological malignancies (2013) (0)
- Loss of heterozygosity among short-term ovarian cancer survivors with germline mutations (2019) (0)
- Paper 5: The Safety and Efficacy of Laparoscopic Surgical Staging of Apparent Stage I Ovarian and Fallopian Tube Cancers (2004) (0)
- Abstract MIP-062: THE EMSY THREONINE 207 PHOSPHO–SITE IS REQUIRED FOR EMSY–DRIVEN SUPPRESSION OF DNA DAMAGE REPAIR (2017) (0)
- Abstract IA9: Pathway-directed therapy (2013) (0)
- Clinical significance of defective mismatch repair in endometrial carcinoma (2005) (0)
- Abstract 70: A role for the chromatin remodeling protein CHD3 in ovarian cancer therapy response (2011) (0)
- Molecular profiling of serous ovarian carcinoma to identify extreme response phenotypes and diagnostic discrepancies. (2014) (0)
- Abstract IA10: Traditional and modern approaches for prevention and early detection (2020) (0)
- Cost-effectiveness analysis of conventional laparoscopic versus robotically assisted laparoscopic adnexal surgery for benign indications performed by gynecologic oncologists (2015) (0)
- Abstract 335: Variable off-target effects of clinically advanced PARP inhibitors (2018) (0)
- Abstract 1938: Implantable nanosensor for non-invasive ovarian cancer biomarker detection with wearable interface (2019) (0)
- Molecular profiling of advanced pelvic serous carcinoma associated with serous tubal intraepithelial carcinoma (2011) (0)
- Outcomes of patients with stage I endometrial cancer in the sentinel lymph node era (2015) (0)
- miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas (2017) (0)
- Abstract IA21: Panel Discussion: Survivorship Issues (2013) (0)
- OP-JNCI170353 787..790 (2018) (0)
- Abstract IA21: Small cell carcinomas of the ovary: Strengths and weaknesses (2018) (0)
- Characteristics of probands with mutations predisposing to gynecologic cancers enrolled in a facilitated cascade testing protocol. (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Douglas A Levine?
Douglas A Levine is affiliated with the following schools:
